Department of Cellular Immunotherapy

Selected publications

Reiche K, Weirauch U, Kreuz M, Fischer L, Gras L, Neumuth T, Platzbecker U, Köhl U, Demlova R, Kremer A, Fröhlich H, Franke S, Merz M; CERTAINTY Consortium. Virtual twins for personalised CAR T-cell therapy in myeloma. Lancet Haematol., 2025 Jul;12(7):e490-e491. doi: 10.1016/S2352-3026(25)00170-X
Jaeckel E, Friedman SL, Hudecek M, Protzer U. Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases. J Hepatol. 2025 Jun 20:S0168-8278(25)02274-3. doi: 10.1016/j.jhep.2025.06.007. Online ahead of print. PMID: 40545042
De Angelis B, D'Amore ML, Lecot P, Neininger K, Lorrain M, Gambotti L, Dreuillet C, Courcault E, Chatterjee S, Delgado J, Galy A, Franz P, Rodriguez-Madoz JR, Cabrerizo Y, Richter A, Girvalaki C, Noviello M, Tassi E, Sanges C, Luu M, Hudecek M, Kremer A, Locatelli F, Negre H, Quintarelli C. European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring. Front Immunol. 2025 Apr 24;16:1567582. doi: 10.3389/fimmu.2025.1567582. eCollection 2025. PMID: 40342422

Mazein A, Shoaib M, Alb M, Sakellariou C, Sommer C, Sewald K, Reiche K, Gogesch P, Roser LA, Ortega Iannazzo S, Sheth S, Schiffmann S, Waibler Z, Neuhaus V, Dehmel S, Satagopam V, Schneider R, Ostaszewski M, Gu W. Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways. J Immunotoxicol. 2024 Oct;21(sup1):S5-S12. doi: 10.1080/1547691X.2024.2345154. Epub 2024 Dec 10. PMID: 39655493
Alb M, Reiche K, Rade M, Sewald K, Loskill P, Cipriano M, Maulana TI, D van der Meer A, Weener HJ, Clerbaux LA, Fogal B, Patel N, Adkins K, Lund E, Perkins E, Cooper C, van den Brulle J, Morgan H, Rubic-Schneider T, Ling H, DiPetrillo K, Moggs J, Köhl U, Hudecek M. Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept. J Immunotoxicol.,2024 Oct;21(sup1):S13-S28. doi: 10.1080/1547691X.2024.2345158. Epub 2024 Dec 10.
Maulana TI, Teufel C, Cipriano M, Roosz J, Lazarevski L, van den Hil F, Scheller L, Orlova V, Koch A, Hudecek M, Alb M, Loskill P. Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells. Cell Stem Cell, 2024 Jul 5;31(7):989-1002.e9. doi: 10.1016/j.stem.2024.04.018. Epub 2024 May 15.

Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. PMID: 35577501 Review.
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. J Immunother Cancer. 2022 May;10(5):e003486. doi: 10.1136/jitc-2021-003486. PMID: 35577500 Review.

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022 Mar;33(3):259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16. PMID: 34923107

Dragon AC, Zimmermann K, Nerreter T, Sandfort D, Lahrberg J, Klöß S, Kloth C, Mangare C, Bonifacius A, Tischer-Zimmermann S, Blasczyk R, Maecker-Kolhoff B, Uchanska-Ziegler B, Abken H, Schambach A, Hudecek M, Eiz-Vesper B. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. J Immunother Cancer. 2020 Oct;8(2):e000736. doi: 10.1136/jitc-2020-000736. PMID: 33127653